Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05192122RecruitingPhase 1
Stop maintenance medicine in multiple myeloma with low remaining disease
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
Chicago, IllinoisAges 18 years+ - NCT05192499Recruiting
Study gut-and-lung bacteria in very young children with asthma
This study looks at whether differences in the body’s bacteria (in the gut and/or airways) can help predict which toddlers with asthma may develop a more severe form. It may help doctors identify children at higher risk earlier so they can be monitored more closely.
Brest, FinistèreAges 1–3 - NCT05193396RecruitingPhase 4
Hydrocortisone trial for adrenal symptoms after stopping steroid pills
This trial tests whether hydrocortisone (a cortisol replacement) helps people who feel symptoms of adrenal insufficiency after they stop long-term prednisolone. It compares hydrocortisone versus placebo to see if symptoms improve and dosing is safer/effective.
AarhusAges 50 years+ - NCT05193591Recruiting
Test antibodies in active lupus with kidney involvement
This study looks at specific immune antibodies (against C1s, HMGB1, and C1q) in adults with systemic lupus erythematosus, especially when lupus is actively affecting the kidneys. It may help researchers better understand what is driving active lupus and who could benefit from future treatments.
GrenobleAges 18 years+ - NCT05193552RecruitingPhase 4
Spirometry study for people with CVID on IG therapy
This trial looks at how breathing tests (spirometry) can help guide treatment decisions for people with CVID and airway disease who are already on immune globulin (IG) therapy. It may help your care team better monitor lung function using a specific breathing-test pattern.
Birmingham, AlabamaAges 21 years+ - NCT05194397RecruitingPhase 2
Exercise plus NR supplement to boost fitness after stem-cell transplant
This trial tests whether a supervised exercise program, plus an NR supplement, can improve fitness in young people who have had an allogeneic (donor) stem-cell transplant for certain blood cancers or bone marrow conditions. It’s meant to help with energy and physical ability while monitoring safety.
Duarte, CaliforniaAges 10–30 - NCT05197192RecruitingPhase 3
New treatment for high-risk CLL using two medicines plus chemo-free pills
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
Bad SaarowAges 18–120 - NCT05197530RecruitingPhase 1
Imaging lymph vessels in rheumatoid arthritis before and during treatment
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
Rochester, New YorkAges 18 years+ - NCT05198661Recruiting
Blood or spinal fluid study in autoimmune brain disorders
This study collects information from people with autoimmune encephalitis or related nerve/brain disorders, using blood and sometimes spinal fluid. It helps researchers better understand these conditions, which may guide future diagnosis and treatments.
Pointe à Pitre, GuadeloupeAges Any age - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT05199532Recruiting
Eosinophilic gut condition registry for children
This study builds a registry of children with eosinophilic gastrointestinal (gut) disorders (EGIDs) and also includes children being evaluated for possible EGIDs. It may help doctors better understand these conditions and improve future care.
Chicago, IllinoisAges 1–25 - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05200715Recruiting
Registry study for inherited and inflammatory eye and joint diseases
This study is a registry, meaning it collects your medical information to better understand several inflammatory (auto-inflammatory) conditions. It may help doctors and researchers improve diagnosis and future treatments for people with these disorders.
AlgiersAges Any age - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05201781RecruitingPhase 4
Long-term follow-up for people previously treated with cilta-cel
This study follows people over time who previously received cilta-cel in a Janssen-sponsored clinical trial. It helps doctors learn about how well the treatment works and how safe it is in the long run.
Phoenix, ArizonaAges 18 years+ - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+ - NCT05203640Recruiting
Strength exercise study for post-menopausal type 1 diabetes
This study checks whether a resistance (strength) exercise program changes blood sugar levels in post-menopausal women with type 1 diabetes. You may be asked to do supervised lab-based exercise sessions near the University of Alberta.
Edmonton, AlbertaAges 45–75 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT05210543Recruiting
Study people after a severe allergic reaction
This trial follows people who have had anaphylaxis (a severe, life-threatening allergic reaction) within the last year. The goal is to better understand what happens over time so doctors can improve care.
BerlinAges Any age - NCT05210907RecruitingPhase 1
Hospital-made CD19 CAR-T for relapsed leukemia in children
This Phase 1 study tests a homemade (hospital-manufactured) immune treatment called CD19 CAR-T for children and teens with a type of leukemia that has come back or did not respond. It may help by targeting leukemia cells that carry the CD19 marker.
SeoulAges birth–25 years - NCT05212792Recruiting
Study genes after COVID vaccine side effects
This study looks at genetic information to better understand why some people develop serious side effects after a COVID-19 vaccine, such as GBS, blood clotting with low platelets (VITT/TTS), or heart inflammation (myocarditis/pericarditis). Your information may help researchers learn who is at higher risk and improve future safety.
Vancouver, British ColumbiaAges 5–99 - NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05214612Recruiting
Predictors of outcomes in myasthenia gravis
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
AsyutAges 16 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.